Are you worried that your pharmacovigilance (PV) system might be missing critical safety signals — putting patient safety and regulatory compliance at risk? If your safety-monitoring, reporting, or data-management processes are outdated or loosely controlled, it can lead to delayed adverse-event detection or even regulatory breaches — undermining the reliability of your PV framework. In this guide, we show how implementing good pharmacovigilance practices (GVP) can restore confidence, integrate robust safety standards into your operations, and ensure continuous compliance after product launch.

Why is continuous monitoring essential for staying aligned with good pharmacovigilance practices?

Effective pharmacovigilance relies on persistent, systematic oversight of medicinal products — not just at launch, but throughout their entire lifecycle. Without continuous monitoring, safety signals may remain undetected until they result in significant harm to patients. Therefore, post‐marketing surveillance is crucial because many adverse reactions (ADRs) — rare side effects, long-term effects, or interactions — only emerge when a medicine is used by a larger, more diverse population, or for a longer time period under real-world conditions.

By embedding continuous monitoring into your PV system, you ensure that any emerging risk is captured in time for assessment, risk-management and, if necessary, mitigation. This process is a core dimension of good pharmacovigilance practices, as defined by regulatory frameworks.

For companies offering medicinal products, a robust PV monitoring structure supports regulatory compliance, builds trust with regulators and stakeholders, and ultimately safeguards patient safety.

How do regulatory updates influence the way companies maintain their PV systems?

Regulatory frameworks for drug safety are dynamic — updates, amendments or new guidances can significantly influence how a company must manage its pharmacovigilance obligations. For a company like Billev Pharma East, staying current means periodically reviewing internal PV procedures, quality-management documentation, and reporting routines. This ensures the PV system remains compliant with legal requirements and maintains readiness for inspections or audits.

Regulatory changes may affect key elements such as adverse event reporting requirements, the structure of the Pharmacovigilance System Master File (PSMF), signal-detection processes or risk-management planning. Adjusting internal processes to reflect these changes is part of embedding good pharmacovigilance practices in a way that withstands evolving legislation and regulatory expectations.

For Billev Pharma East, a proactive approach — monitoring regulatory announcements, updating standard operational procedures (SOPs), training staff and maintaining documentation — is essential to ensure sustainable compliance and robust PV system performance.

Which internal processes should be reviewed regularly to ensure full GVP compliance?

To maintain full compliance with good pharmacovigilance practices, companies should periodically audit and review a set of core internal processes:

• Adverse event (AE) reporting workflows — ensuring all suspected adverse reactions (serious or non-serious) are captured, documented, and reported in line with regulatory timelines.
• Signal detection and assessment procedures — to identify potential safety signals from spontaneous reports, literature, or other sources, and evaluate them systematically.
• Risk management plans (RMPs) and risk-minimisation measures (RMMs) — verifying that known risks remain managed appropriately as new data emerges.
• Documentation and record management — keeping up-to-date PSMF, audit trails, change logs, and ensuring traceability and transparency.
• Quality-management and compliance-monitoring mechanisms — including internal audits, corrective and preventive actions (CAPA), and continuous process evaluations.

Regular review of these processes ensures the PV system stays effective, audit-ready, and aligned with both internal quality standards and regulatory expectations.

For a truly robust pharmacovigilance system, it is vital to periodically examine and reassess the core internal processes that underpin safety oversight, case reporting, signal detection and documentation. Only through regular review can companies ensure that workflows remain efficient, responsibilities clear, and compliance with good pharmacovigilance practices is not just theoretical — but effective in everyday operations. Such vigilance helps prevent lapses that could compromise drug-safety monitoring, regulatory compliance or ultimately patient well-being.

How can organisations detect gaps in their pharmacovigilance quality system before they become risks?

Organisations can uncover weaknesses in their pharmacovigilance quality system by proactively evaluating how their system operates in reality. One effective approach is to perform internal audits or mock-inspections, mimicking what an external regulator might check — reviewing case-management workflows, documentation completeness, record-keeping and compliance with SOPs. Monitoring key performance indicators (KPIs) – such as delays in adverse event reporting, backlog of unresolved cases, unusually high number of follow-ups, or inconsistent data entries — can point to where the system may be failing. Equally important is to examine human and organisational resources: if staff turnover is high or if roles like safety-signal detection, case processing or oversight are understaffed or under-trained, that signals a vulnerability. Another element is assessing whether risk management — including safety-signal detection and follow-up — is still effective when new products, new markets or increased volume are introduced. By instituting a culture of periodic introspection and honest self-assessment, organisations can surface latent gaps early and address them before they translate into compliance failures or, worse, patient-safety incidents.

What indicators reveal that good pharmacovigilance practices are not properly implemented?

There are several red flags that may suggest good pharmacovigilance practices are not being followed adequately. One such indicator is recurrent delays or failures to report suspected adverse drug reactions within the required timelines, or a backlog of unreviewed safety cases. Another warning sign is poor documentation: missing or outdated Pharmacovigilance System Master File, lack of audit trails, absence of version control, or inconsistent records of processes and decisions. If a company lacks defined procedures for signal detection, risk-management planning or follow-up of safety issues, or if staff assigned to pharmacovigilance tasks are insufficiently trained or frequently change, that undermines system stability and consistency. Finally, absence of periodic internal reviews — for example failure to conduct audits, review SOPs or update procedures after regulatory changes — often reveals that the system is static rather than dynamic and may not adapt to evolving safety requirements — a major risk in a regulatory environment that demands flexibility and vigilance.

Recognising these indicators early is vital to restore compliance and ensure a robust safety-monitoring system.

How often should PV procedures be updated to reflect evolving GVP requirements?

PV procedures should be updated whenever there are changes that can impact safety monitoring or regulatory compliance. That includes regulatory updates: as guidance under good pharmacovigilance practices evolves (for example when authorities update modules or guidance documents), companies should promptly revise their procedures. At a minimum, it is necessary to conduct a comprehensive review — including SOPs, PSMF, reporting workflows, responsibilities and staff training — at least once per year, to ensure that the system remains current and functioning as intended. Additionally, any significant internal change — such as launching a new product, entering a new market, re-structuring the PV team, or introducing new data-management tools — should trigger an immediate review and update of relevant PV procedures. Finally, after any safety signal, audit finding or compliance incident, it is necessary to re-examine and adjust procedures to implement corrective and preventive actions. Such a dynamic and responsive approach helps maintain long-term compliance and alignment with GVP standards.

What practical steps help companies maintain long-term compliance with GVP guidelines?

Maintaining long-term compliance with good pharmacovigilance practices requires building a sustainable system — not just a one-time effort. First, a stable quality-management framework must be in place: that includes a properly maintained PSMF, clear definitions of roles and responsibilities (especially for the Qualified Person Responsible for Pharmacovigilance — QPPV), and documented SOPs covering all pharmacovigilance processes. Regular internal audits — ideally risk-based and covering both the PV system and quality-system aspects — help confirm that reality matches documentation, and allow early identification of deviations. Continuous training and retention of PV staff ensures institutional knowledge remains intact and that processes are applied consistently. Where feasible, leveraging modern tools and systems (databases, case-management software, audit-trail systems) can improve data integrity and efficiency. And importantly, a culture of vigilance and transparency — encouraging reporting of suspected ADRs, facilitating open communication, and embracing corrective actions — ensures the system remains alive and responsive rather than static. Over time, these practices help integrate compliance as a core organisational value, not just a regulatory requirement.

Frequently asked questions

Read also:

• How does signal detection integrate with overall signal management in post-market drug safety?
• How do PV requirements influence the role of the QPPV under GVP?
• Which pharmacovigilance vendor criteria truly predict long-term reliability?

Sources: 1 – European Medicines Agency. (n.d.). Good pharmacovigilance practices (GVP), 2 – European Medicines Agency. (n.d.). Guideline on good pharmacovigilance practices (Module I – Pharmacovigilance systems and their quality systems), 3 – European Medicines Agency. (n.d.). Guideline on good pharmacovigilance practices (Module II – Pharmacovigilance System Master File), 4 – European Medicines Agency. (n.d.). Guideline on good pharmacovigilance practices — Risk minimisation measures (Module XVI), 5 – TheRxCloud. (n.d.). What is GVP? A guide to Good Pharmacovigilance Practices, 6 – Scilife. (2025). Good Pharmacovigilance Practices (GVP) explained — structure, compliance and audit-readiness, 7 – CCRPS. (n.d.). Good Pharmacovigilance Practice Explained, 8 – Wikipedia contributors. (n.d.). Good clinical practice. In Wikipedia.

Image credits:

In-article image: Photo by Roman Rutkovskuy by Unsplash

Hero image: Photo by Myriam Zilles by Unsplash